Curry Richard C, Dahiya Saurabh, Alva Venur Vyshak, Raizer Jeffrey J, Ahluwalia Manmeet S
Department of Hematology/Oncology, The University of Cincinnati, Cincinnati, OH, USA.
Expert Rev Anticancer Ther. 2015 Apr;15(4):387-97. doi: 10.1586/14737140.2015.1028376.
The survival of patients with high-grade gliomas (anaplastic gliomas and glioblastoma) remains poor despite current treatment modalities. However, an enhanced understanding of gliomagenesis is supporting the development of targeted molecular therapies with the potential for improving clinical outcomes. Glioblastoma (GBM) is characterized by extensive microvascular proliferation and the production of large amounts of VEGF. Bevacizumab is a humanized IgG1 monoclonal antibody that selectively binds with high affinity to human VEGF and neutralizes VEGF's biologic activity. Preclinical data indicate that angiogenesis is essential for the proliferation and survival of GBM cells. A number of studies have evaluated the outcomes of both newly diagnosed and recurrent GBM patients with bevacizumab in a prospective manner. Here, we discuss the role of bevacizumab in the treatment of anaplastic gliomas and GBM in the recurrent and upfront setting.
尽管有当前的治疗方式，但高级别胶质瘤（间变性胶质瘤和胶质母细胞瘤）患者的生存率仍然很低。然而，对胶质瘤发生机制的深入了解正在推动靶向分子疗法的发展，这些疗法有可能改善临床结果。胶质母细胞瘤（GBM）的特征是广泛的微血管增殖和大量VEGF的产生。贝伐单抗是一种人源化IgG1单克隆抗体，它以高亲和力选择性地与人VEGF结合，并中和VEGF的生物活性。临床前数据表明，血管生成对于GBM细胞的增殖和存活至关重要。许多研究以前瞻性方式评估了使用贝伐单抗治疗新诊断和复发性GBM患者的结果。在此，我们讨论贝伐单抗在复发和初始治疗环境中治疗间变性胶质瘤和GBM的作用。
